Aditxt Inventory 2020-2024 | ADTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Aditxt inventory from 2020 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Aditxt inventory from 2020 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.7B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$19.3B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.4B
Summit Therapeutics (SMMT)	$13.6B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$11.8B
Catalent (CTLT)	$10.8B
Jazz Pharmaceuticals (JAZZ)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7.2B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.3B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2.4B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Centessa Pharmaceuticals (CNTA)	$2.1B
Evotec AG (EVO)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.7B
Recursion Pharmaceuticals (RXRX)	$1.6B
Harrow (HROW)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Cassava Sciences (SAVA)	$1.5B